financetom
Business
financetom
/
Business
/
Realme to launch X7 and X7 Pro smartphones in India next month
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Realme to launch X7 and X7 Pro smartphones in India next month
Jan 21, 2021 4:48 AM

Smartphone brand Realme is set to launch two new smartphones -- Realme X7 and Realme X7 Pro -- in India in the first week of February.

Industry sources told IANS on Wednesday that Realme X7 and X7 Pro will be powered by MediaTek octa core Dimensity 800U processors and support 5G connectivity.

While X7 Pro features the MediaTek Dimensity 1000+ SoC, the Realme X7 will house the Dimensity 800U SoC.

The Realme X7 series also offer punch-hole AMOLED display, 64MP quad-camera setup, among other exciting features.

The MediaTek SoC comes with MediaTek 5G UltraSave technology. The chipset can get 2.3Gbps download speeds and is built using a 7nm process.

It has an octa-core CPU with a dual cluster consisting of two Arm Cortex-A76 processors with a clock speed of 2.4GHz.

The company on Wednesday announced that it will also be one of the first brands to introduce a smartphone with MediaTek's new Dimensity 1200 flagship 5G smartphone chip, likely to be called X9, to build a dual flagship portfolio in 2021.

"We will continue to work closely with MediaTek to foster development, adoption and large-scale popularity of 5G around the world," Madhav Sheth, Vice President, Realme and CEO, Realme India and Europe said in a statement.

MediaTek launched the Dimensity 1200 flagship 5G smartphone chip that comes with a 6nm advanced production process, bringing powerful performance and lower power consumption.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
2seventy bio, Bristol Myers Discontinue Phase 3 Abecma Study; Shares Fall Pre-Bell
2seventy bio, Bristol Myers Discontinue Phase 3 Abecma Study; Shares Fall Pre-Bell
Oct 3, 2024
06:57 AM EDT, 09/25/2024 (MT Newswires) -- 2seventy bio (TSVT) said Wednesday it would discontinue enrollment for the ongoing phase 3 study of Abecma with lenalidomide maintenance as treatment for newly diagnosed multiple myeloma due to scarce eligible patients for the trial. Shares of the company were down 7.3% in recent premarket activity. Treatments for NDMM have improved considerably since...
Judge Rules Against New York Law Requiring Uber, DoorDash to Share Data With Restaurants
Judge Rules Against New York Law Requiring Uber, DoorDash to Share Data With Restaurants
Oct 3, 2024
06:59 AM EDT, 09/25/2024 (MT Newswires) -- A federal judge ruled on Tuesday that a New York City law requiring food delivery services such as Uber (UBER) Eats, DoorDash ( DASH ) and Grubhub to share customer names and contact details with restaurants is unconstitutional, media outlets reported. The judge ruled that the 2021 law meant to help restaurants recover...
Merck's colorectal cancer therapy fails late-stage trial
Merck's colorectal cancer therapy fails late-stage trial
Oct 3, 2024
(Reuters) -Merck ( MRK ) said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer. The company said patients who took its experimental drug favezelimab in combination with Keytruda did not show significant improvement in overall survival compared to standard-of-care treatment. The combination therapy is...
--Merck Says Phase 3 Trial of Colorectal Cancer Combination Therapy Did Not Meet Primary Endpoint
--Merck Says Phase 3 Trial of Colorectal Cancer Combination Therapy Did Not Meet Primary Endpoint
Oct 3, 2024
06:58 AM EDT, 09/25/2024 (MT Newswires) -- Price: 114.69, Change: -0.27, Percent Change: -0.23 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved